Progenics Pharmaceuticals, Inc. is now a
subsidiary of Lantheus Holdings, Inc.
About Us About Us

Find, Fight and FollowTM .

Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (PSMA) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has three commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which are partnered with Bausch Health Companies Inc.

Progenics is proud to have joined the Lantheus family. Lantheus, a global leader in the field of medical imaging, develops, manufactures and commercializes essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care. These pioneering products assist physicians in the diagnosis of conditions affecting the heart, brain, lungs and other organs using echocardiography and nuclear imaging. We are pleased to add a pipeline of radiotherapeutics, targeted PET imaging agents and small molecule therapeutics in the oncology space to the Lantheus portfolio.